[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Rezolute Inc (RZLT)

Rezolute Inc (RZLT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 385,168
  • Shares Outstanding, K 96,292
  • Annual Sales, $ 0 K
  • Annual Income, $ -74,410 K
  • EBIT $ -87 M
  • EBITDA $ -90 M
  • 60-Month Beta 0.68
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.16

Options Overview Details

View History
  • Implied Volatility 152.89% (-17.75%)
  • Historical Volatility 70.41%
  • IV Percentile 49%
  • IV Rank 24.37%
  • IV High 422.56% on 03/11/26
  • IV Low 66.01% on 07/07/25
  • Expected Move (DTE 5) 0.08 (1.91%)
  • Put/Call Vol Ratio 0.45
  • Today's Volume 96
  • Volume Avg (30-Day) 1,008
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 38,321
  • Open Int (30-Day) 28,351
  • Expected Range 3.92 to 4.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.13
  • Number of Estimates 2
  • High Estimate $-0.12
  • Low Estimate $-0.14
  • Prior Year $-0.26
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.83 +41.34%
on 05/19/26
4.70 -14.98%
on 06/04/26
+0.70 (+21.21%)
since 05/12/26
3-Month
2.29 +74.67%
on 03/19/26
4.70 -14.98%
on 06/04/26
+0.98 (+32.45%)
since 03/12/26
52-Week
1.07 +273.83%
on 12/11/25
11.46 -65.09%
on 11/10/25
-0.40 (-9.09%)
since 06/12/25

Most Recent Stories

More News
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

REDWOOD CITY, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia...

RZLT : 4.00 (+3.63%)
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

Study now 50% enrolled 6 of 8 participants have already met the responder criterion for the study’s primary endpoint Topline results for the fully enrolled open-label study are expected in...

RZLT : 4.00 (+3.63%)
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused...

RZLT : 4.00 (+3.63%)
Rezolute Reports Earnings After Presenting Data That Already Told Investors What the FDA Wants to Hear

Barchart Research What to Expect from RZLT Earnings RZLT Generated May 11, 2026 Current Price $3.17 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 5.17% Rezolute Reports Earnings After...

RZLT : 4.00 (+3.63%)
Rezolute to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused...

RZLT : 4.00 (+3.63%)
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting

Includes results from additional continuous glucose monitoring (CGM)-based outcomes which demonstrate significant and consistent improvements in glycemic control in ersodetug treatment arms compared to...

RZLT : 4.00 (+3.63%)
Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting

Oral presentation will include previously announced topline results as well as pre-specified and post-hoc data updates REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq:...

RZLT : 4.00 (+3.63%)
Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting

REDWOOD CITY, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”),  a late-stage rare disease company focused on treating hypoglycemia caused...

RZLT : 4.00 (+3.63%)
RZLT INVESTOR ALERT: Faruqi & Faruqi, LLP Launches Investigation into Rezolute

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss...

RZLT : 4.00 (+3.63%)
INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute (RZLT)

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options

RZLT : 4.00 (+3.63%)

Business Summary

Rezolute, Inc. is a biopharmaceutical company specializing in the development of drug therapies for metabolic and orphan diseases. The Company's products include AB101, RZ358, RZ402 and RZ602 which are in clinical stage. Rezolute, Inc., formerly known as AntriaBio, Inc., is based in LOUISVILLE, United...

See More

Key Turning Points

3rd Resistance Point 4.57
2nd Resistance Point 4.40
1st Resistance Point 4.20
Last Price 4.00
1st Support Level 3.83
2nd Support Level 3.66
3rd Support Level 3.46

See More

52-Week High 11.46
Fibonacci 61.8% 7.49
Fibonacci 50% 6.26
Fibonacci 38.2% 5.04
Last Price 4.00
52-Week Low 1.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.